Withdrawal from methylphenidate increases neural reactivity of dorsal midbrain

Neuroscience Research

Volumn 68, Issue 4, 2010, Pages 290-300

  Ferreira, R ^a   Bassi, G S ^a   Cabral, A ^a   Nobre, M J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anxiety; Brainstem; Methylphenidate; Withdrawal

Indexed keywords

CORTICOSTERONE; METHYLPHENIDATE; PROTEIN FOS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN DEPTH STIMULATION; BRAIN STEM; CELL ACTIVATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEVELOPMENTAL STAGE; DRUG MEGADOSE; DRUG WITHDRAWAL; GROOMING; IMMUNOREACTIVITY; MALE; MAZE TEST; MESENCEPHALON; NERVE CELL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REARING; SPINE; STARTLE REFLEX;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; MALE; MAZE LEARNING; MESENCEPHALON; METHYLPHENIDATE; NEURONS; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 78149447783     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2010.08.009     Document Type: Article

References (100)

1. Accardo P., Blondis T.A. What's all the fuss about Ritalin?. J. Pediatry 2001, 138:6-9.
2. Anseloni V.Z., Brandão M.L. Ethopharmacological analysis of behavior of rats using variations of the elevated plus-maze. Behav. Pharmacol. 1997, 8:533-540.
3. Askenasy E.P., Taber K.H., Yang P.B., Dafny N. Methylphenidate (Ritalin): behavioral studies in the rat. Int. J. Neurosci. 2007, 6:757-794.
4. Avila M.A., Ruggiero R.N., Cabral A., Brandão M.L., Nobre M.J., Castilho V.M. Involvement of the midbrain tectum in the unconditioned fear promoted by morphine withdrawal. Eur. J. Pharmacol. 2008, 590:217-223.
5. Beck C.H., Fibiger H.C. Conditioned fear-induced changes in behavior and in the expression of the immediate early gene c-fos: with and without diazepam pretreatment. J. Neurosci. 1995, 15:709-720.
6. Beckett S.R., Duxon M.S., Aspley S., Marsden C.A. Central c-fos expression following 20kHz/ultrasound induced defence behavior in the rat. Brain Res. Bull. 1997, 42:421-426.
7. Biederman J., Faraone S., Mick E., Wozniak J., Chen L., Ouellette C., Marrs A., Moore P., Garcia J., Mennin D., Lelon E. Attention-deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity?. J. Am. Acad. Child. Adolesc. Psychiatry 1996, 35:997-1008.
8. Bolaños C.A., Barrot M., Berton O., Wallace-Black D., Nestler E.J. Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biol. Psychiatry 2003, 54:1317-1329.
9. Borelli K.G., Nobre M.J., Brandão M.L. Effects of acute and chronic fluoxetine and diazepam on freezing behavior induced by electrical stimulation of dorsolateral and lateral columns of the periaqueductal gray matter. Pharmacol. Biochem. Behav. 2004, 77:557-566.
10. Brandão M.L., Anseloni V.Z., Pandossio J.E., De Araujo J.E., Castilho V.M. Neurochemical mechanisms of the defensive behavior in the dorsal midbrain. Neurosci. Biobehav. Rev. 1999, 23:863-875.
11. Brandão M.L., Troncoso A.C., de Souza Silva M.A., Huston J.P. The relevance of neuronal substrates of defense in the midbrain tectum to anxiety and stress: empirical and conceptual considerations. Eur. J. Pharmacol. 2003, 463:225-233.
12. Brandão M.L., Borelli K.G., Nobre M.J., Santos J.M., Albrechet-Souza L., Oliveira A.R., Martinez R.C. Gabaergic regulation of the neural organization of fear in the midbrain tectum. Neurosci. Biobehav. Rev. 2005, 29:1299-1311.
13. Brandon C.L., Marinelli M., White F.J. Adolescent exposure to methylphenidate alters activity of rat midbrain dopamine neurons. Biol. Psychiatry 2003, 54:1338-1344.
14. Browne R.G., Segal D.S. Metabolic and experiential factors in the behavioral response to repeated amphetamine. Pharmacol. Biochem. Behav. 1977, 6(5):545-552.
15. Cabral A., De Ross J., Castilho V.M., Brandão M.L., Nobre M.J. Glutamate receptor antagonism in inferior colliculus attenuates elevated startle response of high anxiety diazepam-withdrawn rats. Neuroscience 2009, 161:707-717.
16. Campeau S., Falls W.A., Cullinan W.E., Helmreich D.L., Davis M., Watson S.J. Elicitation and reduction of fear: behavioral and neuroendocrine indices and brain induction of the immediate-early gene c-fos. Neuroscience 1997, 78:1087-1104.
17. Carlezon W.A., Mague S.D., Andersen S.L. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol. Psychiatry 2003, 54:1330-1337.
18. Castilho V.M., Avanzi V., Brandão M.L. Antinociception elicited by aversive stimulation of the inferior colliculus. Pharmacol. Biochem. Behav. 1999, 62:425-431.
19. Castilho V.M., Borelli K.G., Brandão M.L., Nobre M.J. Anxiety-like symptoms induced by morphine withdrawal may be due to the sensitization of the dorsal periaqueductal gray. Physiol. Behav. 2008, 94:552-562.
20. Challman T.D., Lipsky J.J. Methylphenidate: its pharmacology and uses. Mayo Clin. Proc. 2000, 75:711-721.
21. Charney D.S., Grillon C., Bremner J.D. The neurobiological basis of anxiety and fear: circuits, mechanisms and neurochemical interactions (part I). Neuroscientist 1998, 4. 35-44.
22. Chase T.D., Carrey N., Brown R.E., Wilkinson M. Methylphenidate differentially regulates c-fos and fos B expression in the developing rat striatum. Brain Res. Dev. Brain Res. 2005, 157:181-191.
23. Conti L.H., Berridge C.W., Tayler J.E. Both corticotropin-releasing factor and apomorphine reduce prepulse inhibition following repeated central infusion of corticotropin-releasing factor. Pharmacol. Biochem. Behav. 2006, 85:261-272.
24. Crawford C.A., McDougall S.A., Meier T.L., Collins R.L., Watson J.B. Repeated methylphenidate treatment induces behavioral sensitization and decreases protein kinase A and dopamine-stimulated adenylyl cyclase activity in the dorsal striatum. Psychopharmacology (Berl) 1998, 136:34-43.
25. Cruz A.P., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 1994, 49:171-176.
26. Davis M. Neurochemical modulation of sensory-motor reactivity: acoustic and tactile startle reflexes. Neurosci. Biobehav. Rev. 1980, 4:241-263.
27. Davis M., Redmond D.E., Baraban J.M. Noradrenergic agonists and antagonists: effects on conditioned fear as measured by the potentiated startle paradigm. Psychopharmacology (Berl) 1979, 65:111-118.
28. Davis M., Falls W.A., Campeau S., Kim M. Fear-potentiated startle: a neural and pharmacological analysis. Behav. Brain Res. 1993, 58:175-198.
29. Del Arco A., Mora F. Neurotransmitters and prefrontal cortex-limbic system interactions: implications for plasticity and psychiatric disorders. J. Neural Transm. 2009, 116:941-952.
30. DelBello M.P., Soutullo C.A., Hendricks W., Niemeier R.T., McElroy S.L., Strakowski S.M. Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disord. 2001, 3:53-57.
31. Eckermann K., Beasley A., Yang P., Gaytan O., Swann A., Dafny N. Methylphenidate sensitization is modulated by valproate. Life Sci. 2001, 69:47-57.
32. Ferreira-Netto C., Borelli K.G., Brandão M.L. Neural segregation of Fos-protein distribution in the brain following freezing and escape behaviors induced by injections of either glutamate or NMDA into the dorsal periaqueductal gray of rats. Brain Res. 2005, 1031:151-163.
33. Floyd N.S., Price J.L., Ferry A.T., Keay K.A., Bandler R. Orbitomedial prefrontal cortical projections to distinct longitudinal columns of the periaqueductal gray in the rat. J. Comp. Neurol. 2000, 422:556-578.
34. Fontanesi L.B., Ferreira R., Cabral A., Castilho V.M., Brandão M.L., Nobre M.J. Brainstem areas activated by diazepam withdrawal as measured by Fos-protein immunoreactivity in rats. Brain Res. 2007, 1166:35-46.
35. Gatley S.J., Pan D.F., Chen R., Chaturvedi G., Ding Y.S. Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci. 1996, 58:231-239.
36. Gaytan O., al-Rahim S., Swann A., Dafny N. Sensitization to locomotor effects of methylphenidate in the rat. Life Sci. 1997, 61(8). PL101-7.
37. Gaytan O., Nason R., Alagugurusamy R., Swann A., Dafny N. MK-801 blocks the development of sensitization to the locomotor effects of methylphenidate. Brain Res. Bull. 2000, 51(6):485-492.
38. Gaytan O., Swann A.C., Dafny N. Disruption of sensitization to methylphenidate by a single administration of MK-801. Life Sci. 2002, 70(19):2271-2285.
39. Gerasimov M.R., Franceschi M., Volkow N.D., Rice O., Schiffer W.K., Dewey S.L. Synergistic interactions between nicotine and cocaine or methylphenidate depends on the dose of dopamine transporter inhibitor. Synapse 2000, 15:432-437.
40. Giedd J.N. Bipolar disorder and attention-deficit/hyperactivity disorder in children and adolescents. J. Clin. Psychiatry 2000, 61(9):31-34.
41. Goldstein R.Z., Volkow N.D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry 2002, 159:1642-1652.
42. Graeff F.G. Brain defense systems and anxiety. Handbook of Anxiety 1990, 307-354. Elsevier, New York. M. Roth, G.D. Burrow, R. Noyes (Eds.).
43. Graeff F.G. Neuroanatomy and neurotransmitter regulation of defensive behaviors and related emotions in mammals. Braz. J. Med. Biol. Res. 1994, 27:811-829.
44. Graeff F.G. Serotonin, the periaqueductal gray and panic. Neurosci. Biobehav. Rev. 2004, 28:239-259.
45. Graeff F.G., Brandão M.L., Audi E.A., Schultz M.T.B. Modulation of the brain aversive system by GABAergic and serotonergic mechanisms. Behav. Brain Res. 1986, 21:65-72.
46. Grillon C. Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology. Biol. Psychiatry 2002, 52:958-975.
47. Hauger R.L., Hulihan-Giblin B., Skolnick P., Paul S.M. Characteristics of [3H](+)-amphetamine binding sites in the rat central nervous system. Life Sci. 1984, 34:771-782.
48. Hurd Y.L., Ungerstdet U. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur. J. Pharmacol. 1989, 166:251-260.
49. Izenwasser S., Coy A.E., Ladenhein B., Loeloff R.J., Cadet J.L., Dawn F. Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur. J. Pharmacol. 1999, 373:187-193.
50. Jaffe S.L. Intranasal abuse of prescribed methylphenidate by an alcohol and drug abuse adolescents with ADHD. J. Am. Acad. Child. Adolesc. Psychiatry 1991, 30:773-775.
51. Kauer-Sant'Anna M., Kapczinski F., Vieta E. Epidemiology and management of anxiety in patients with bipolar disorder. CNS Drugs 2009, 23:953-964.
52. Koehler-Troy C., Strober M., Malenbaum R. Methylphenidate-induced mania in a prepubertal child. J. Clin. Psychiatry 1986, 47:566-567.
53. Kollins S.H. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J. Clin. Psychiatry 2003, 64:14-18.
54. Kollins S.H., MacDonald E.K., Rush C.R. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol. Biochem. Behav. 2001, 68:611-627.
55. Koob G.F., Sanna P.P., Bloom F.E. Neuroscience of addiction. Neuron 1998, 21:467-476.
56. Kuczenski R., Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin and norepinephrine: comparisons with amphetamine. J. Neurochem. 1997, 68:2032-2037.
57. Kuczenski R., Segal D.S. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J. Neurosci. 2002, 22:7264-7271.
58. Lamprea M.R., Cardenas F.P., Vianna D.M., Castilho V.M., Cruz-Morales S.E., Brandão M.L. The distribution of Fos immunoreactivity in rat brain following freezing and escape responses elicited by electrical stimulation of the inferior colliculus. Brain Res. 2002, 950:186-194.
59. Leonard B.E., McCartan D., White J., King D.J. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum. Psychopharmacol. 2004, 19:151-180.
60. Liebsch G., Montkowski A., Holsboer F., Landgraf R. Behavioral profiles of two Wistar rat lines selectively bred for high or low anxiety-related behavior. Behav. Brain Res. 1998, 94:301-310.
61. Lin J.S., Hou Y., Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc. Natl. Acad. Sci. U.S.A. 1996, 93(24):14128-14133.
62. McNamaraa C.G., Davidson E.S., Schenk S. A comparison of the motor-activating effects of acute and chronic exposure to amphetamine and methylphenidate. Pharmacol. Biochem. Behav. 1993, 45(3):729-732.
63. Moll G.H., Hause S., Rüther E., Rothenberger A., Huether G. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J. Child. Adolesc. Psychoparmacol. 2001, 11:15-24.
64. Nunes Mamede Rosa M.L., Nobre M.J., Ribeiro O.A., Brandão M.L. Isolation-induced changes in ultrasonic vocalization, fear-potentiated startle and prepulse inhibition in rats. Neuropsychobiology 2005, 51:248-255.
65. Oliveira L.C., Broiz A.C., de Macedo C.E., Landeira-Fernandez J., Brandão M.L. 5-HT2 receptor mechanisms of the dorsal periaqueductal gray in the conditioned and unconditioned fear in rats. Psychopharmacology (Berl) 2007, 191:253-262.
66. Otto M.W., Simon N.M., Wisniewski S.R., Miklowitz D.J., Kogan J.N., Reilly-Harrington N.A., Frank E., Nierenberg A.A., Marangell L.B., Sagduyu K., Weiss R.D., Miyahara S., Thas M.E., Sachs G.S., Pollack M.H. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br. J. Psychiatry 2006, 189:20-25.
67. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2005, Elsevier, San Diego. 5th ed.
68. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
69. Pierce R.C., Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?. Neurosci. Biobehav. Rev. 2006, 30:215-238.
70. Pini S., Cassano G.B., Simonini E., Savino M., Russo A., Montgomery S.A. Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia. J. Affect. Disord. 1997, 42:145-153.
71. Reep R.L., Winans S.S. Efferent connections of dorsal and ventral agranular insular cortex in the hamster, Mesocricetus auratus. Neuroscience 1982, 7:2609-2635.
72. Ritz M.C., Lam R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 237:1219-1223.
73. Ross R.G. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am. J. Psychiatry 2006, 163:1149-1152.
74. Rosse R.B., Johri S.K., Deutsch S.I. Pupillary changes associated with the development of stimulant-induced mania: a case report. Clin. Neuropharmacol. 1997, 20:270-275.
75. Sandner G., Oberling P., Silveira M.C., Di Scala G., Rocha B., Bagri A., Depoortere R. What brain structures are active during emotions? Effects of brain stimulation elicited aversion on c-fos immunoreactivity and behavior. Behav. Brain Res. 1993, 58:9-18.
76. Schaeffer J.L., Ross R.G. Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. J. Am. Acad. Child. Adolesc. Psychiatry 2002, 41:538-545.
77. Segal D.S., Kuczenski R. Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile. J. Pharmacol. Exp. Ther. 1999, 291:19-30.
78. Senba E., Matsunaga K., Tohyama M., Noguchi K. Stress-induced c-fos expression in the rat brain: activation mechanism of sympathetic pathway. Brain Res. Bull. 1993, 31:329-344.
79. Silveira M.C., Sandner G., Graeff F.G. Induction of Fos immunoreactivity in the brain by exposure to the elevated plus-maze. Behav. Brain Res. 1993, 56:115-118.
80. Silveira M.C., Sandner G., Di Scala G., Graeff F.G. c-Fos immunoreactivity in the brain following electrical or chemical stimulation of the medial hypothalamus of freely moving rats. Brain Res. 1995, 674:265-274.
81. Simon N.M., Otto M.W., Wisniewski S.R., Fossey M., Sagduyu K., Frank E., Sachs G.S., Nierenberg A.A., Thase M.E., Pollack M.H. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am. J. Psychiatry 2004, 161:2222-2229.
82. Simon N.M., Zalta A.K., Otto M.W., Ostacher M.J., Fischmann D., Chow C.W., Thompson E.H., Stevens J.C., Demopulos C.M., Nierenberg A.A., Pollack M.H. The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorder. J. Psychiatr. Res. 2007, 41:255-264.
83. Singewald N., Sharp T. Neuroanatomical targets of anxiogenic drugs in the hindbrain as revealed by Fos immunocytochemistry. Neuroscience 2000, 98:759-770.
84. Solanto M.V. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav. Brain Res. 1998, 94:127-152.
85. Sonders M.S., Zhu S.J., Zahniser N.R., Kavanaugh M.P., Amara S.G. Multiple ionic conductances of the human dopamine transporter: the action of dopamine and psychostimulants. J. Neurosci. 1997, 17:960-974.
86. Souza-Pinto L.F., Castilho V.M., Brandão M.L., Nobre M.J. The blockade of AMPA-kainate and NMDA receptors in the dorsal periaqueductal gray reduces the effects of diazepam withdrawal in rats. Pharmacol. Biochem. Behav. 2007, 87:250-257.
87. Spencer T., Biederman J., Wilens T., Harding M., O'Donnel D., Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Am. Acad. Child. Adolesc. Psychiatry 1996, 35:409-432.
88. Sripadab S., Gaytana O., Al-rahima B.S., Swannb A., Dafnya N. Dose-related effects of MK-801 on acute and chronic methylphenidate administration. Brain Res. 1998, 814(14):78-85.
89. Trinh J.V., Nehrenberg D.L., Jacobsen J.P., Caron M.G., Wetsel W.C. Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice. Neuroscience 2003, 118(2):297-310.
90. Unis A.S., Dawson T.M., Gehlert D.R., Wamsley J.K. Autoradiographic localization of [3H]methylphenidate binding sites in rat brain. Eur. J. Pharmacol. 1985, 113:155-157.
91. Vianna D.M., Borelli K.G., Ferreira-Netto C., Macedo C.E., Brandão M.L. Fos-like immunoreactive neurons following electrical stimulation of the dorsal periaqueductal gray at freezing and escape thresholds. Brain Res. Bull. 2003, 62:179-189.
92. Vivian J.A., Farrell W.J., Sapperstein S.B., Miczek K.A. Diazepam withdrawal: effects of diazepam and gepirone on acoustic startle-induced 22kHz ultrasonic vocalizations. Psychopharmacology 1994, 114:101-108.
93. Volkow N.D., Wang G.J., Fowler J.S., Fischman M., Foltin R., Abumrad N.N., Gatley S.J., Logan J., Wong C., Gifford A., Ding Y.S., Hitzemann R., Pappas N. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci. 1999, 65:L7-L12.
94. Winslow J.T., Parr L.A., Davis M. Acoustic startle, prepulse inhibition, and fear-potentiated startle measured in rhesus monkeys. Biol. Psychiatry 2002, 51:859-866.
95. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol. Rev. 1987, 94:469-492.
96. Wood W.G., Schreiber H.L., Villescas R., Carlson R.H. Effects of prior experience and 'functional disturbance' on acute and chronic tolerance to methylphenidate. Psychopharmacology (Berl) 1997, 51:165-168.
97. Yang P., Singhal N., Modi G., Swann A., Dafny N. Effects of lithium chloride on induction and expression of methylphenidate sensitization. Eur. J. Pharmacol. 2001, 426(1-2):65-72.
98. Yang P.B., Swann A.C., Dafny N. Chronic methylphenidate modulates locomotor activity and sensory evoked responses in the VTA and NAc of freely behaving rats. Neuropharmacology 2006, 51:546-556.
99. Young L.T., Cooke R.G., Robb J.C., Levitt A.J., Joffe R.T. Anxious and non-anxious bipolar disorder. J. Affect. Disord. 1993, 29:49-52.
100. Zito J.M., Safer D.J., dos Reis S., Gardner J.F., Boles M., Lynch F. Trends in the prescribing of psychotropic medication to preschoolers. J. Am. Med. Assoc. 2000, 283:1025-1030.